WithdrawnPhase 2

NRX-1074 in Early Course Schizophrenia

Stopped: The study was withdrawn by the sponsor.

United States0

Plain-language summary

This study seeks to examine the effectiveness of NRX-1074 in the treatment of negative symptoms and cognition in schizophrenia compared to other agents at the glycine site which have demonstrated inconsistent results for negative symptoms. In addition to testing efficacy, we will examine the time course of response of symptoms as well as any effects on memory consolidation.

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18-50 * Diagnosis of Schizophrenia, Schizophreniform, or schizoaffective disorder as per DSM-V criteria * Within five years of onset of illness * Treated with any antipsychotic agent except clozapine at an adequate, stable dose for at least 8 weeks. * A score of at least 4 (moderate) on at least one BPRS negative symptom item. Exclusion Criteria: * Serious or unstable medical illness * Pregnant or nursing * Abuse of substances except nicotine in the previous 6 weeks (excluding cannabis use) * Positive urine toxicology at screening * Experiencing serious suicidal or homicidal ideation within six months * Treatment with clozapine

What they're measuring

Brief Psychiatric Rating Scale (BPRS) total score

Timeframe: Day 8

Trial details

NCT IDNCT02603458

SponsorNYU Langone Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-08

View on ClinicalTrials.gov More Schizophrenia trials